Podcast

Updates in Advanced HER2-Positive Breast Cancer

Author(s):

OncLive Staff

Dr Mahtani and colleagues highlight key clinical trials such as DESTINY-Breast01, HER2CLIMB, NALA, and SOPHIA in the setting of advanced HER2-positive breast cancer and discuss the practical considerations of these data.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina
Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity
View More
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas
Video

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

May 1st 2025 - Jun 6th 2025

online-activity
View More
From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment
Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

May 1st 2025 - May 2nd 2026

online-activity
View More
Related Content
Giants of Cancer Care® 13th Annual Class
May 7th 2025

Giants of Cancer Care® Announces the 13th Annual Class of Inductees

Anna C. Pavlick, BSN, MSc, DO, MBA, professor, medicine, Division of Hematology & Medical Oncology, Weill Cornell Medicine; founding director, Cutaneous Oncology Program, Weill Cornell Medicine and NewYork-Presbyterian
May 5th 2025

RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA

Invasive Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
May 2nd 2025

5-Year Phase 2 Data Show 0% Recurrence Rate After Surgery Omission in Select Patients With Invasive Breast Cancer

Nicole Lamanna, MD, hematologic oncologist, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian/Columbia University Irving Medical Center
April 28th 2025

Disease Features and Treatment Intolerance Inform Pirtobrutinib Use in Pretreated CLL: With Nicole Lamanna, MD

HR+ Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 29th 2025

Avutometinib/Abemaciclib/Fulvestrant Combo Is Active, Safe in CDK4/6 Inhibitor–Resistant HR+/HER2– Metastatic Breast Cancer

Breast Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
April 28th 2025

Bria-IMT Plus Checkpoint Inhibition Is Safe and Yields Clinical Benefit in Pretreated Metastatic Breast Cancer